Gamma Secretase (EC 3.4.23.) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Gamma Secretase (EC 3.4.23.)- Pipeline Review, H2 2019’, provides in depth analysis on Gamma Secretase (EC 3.4.23.) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders, Cardiovascular and Non Malignant Disorders under development targeting Gamma Secretase (EC 3.4.23.).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)

– The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects

– The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“AlzeCure Pharma AB

Astellas Pharma Inc

Audion Therapeutics BV

Ayala Pharmaceuticals Inc

Bristol-Myers Squibb Co

Cotinga Pharmaceuticals Inc

Eli Lilly and Co

Everfront Biotech Inc

Lipopharma Therapeutics SL

Merck & Co Inc

NeuroGenetic Pharmaceuticals Inc

Pharchoice Therapeutics Inc

Pipeline Therapeutics Inc

SpringWorks Therapeutics Inc

Takeda Pharmaceutical Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gamma Secretase (EC

3.4.23.) Overview

Gamma Secretase (EC

3.4.23.) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Gamma Secretase (EC

3.4.23.) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gamma Secretase (EC

3.4.23.) Companies Involved in Therapeutics Development

Bristol-Myers Squibb Co

Cotinga Pharmaceuticals Inc

Lipopharma Therapeutics SL

Merck & Co Inc

NeuroGenetic Pharmaceuticals Inc

SpringWorks Therapeutics LLC

Stemline Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Gamma Secretase (EC

3.4.23.) Drug Profiles

BMS-932481 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986133 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate PSEN1 for Heart Failure Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSI-34 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-226A1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3056480 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGP-555 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nirogacestat Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit PSEN1 for Alzheimer’s Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-301 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-302 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta and Gamma Secretase for Alzheimer's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Gamma Secretase for Hearing Loss Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PSEN1 for Alzheimer's Disease Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gamma Secretase (EC

3.4.23.) Dormant Products

Gamma Secretase (EC

3.4.23.) Discontinued Products

Gamma Secretase (EC

3.4.23.) Product Development Milestones

Featured News & Press Releases

Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer’s Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers

Nov 10, 2015: NeuroGenetic Pharmaceuticals Awarded $2.5 Million Grant From NIA to Conduct Clinical Trials with NGP 555 to Treat and Prevent Alzheimer’s Disease; Reports Initial Results of Phase 1a Clinical Trial

Sep 29, 2014: FDA Approves NeuroGenetic Pharmaceuticals Application to Begin Clinical Trials for Its NGP 555 Compound to Treat and Prevent Alzheimer’s Disease

Jun 16, 2014: Prof. G.L. Nicolson and Prof. R.M. Epand join Lipopharma's SAB

Jul 15, 2011: NeuroGenetic Pharma Receives SBIR Grant For Preclinical Development And IND Application Of NGP 555 To Treat Alzheimer's Disease

Jul 21, 2009: Critical Outcome Technologies Inc. Announces The Launch Of A Drug Discovery Program For Alzheimer’S Disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AlzeCure Pharma AB, H2 2019

Pipeline by Astellas Pharma Inc, H2 2019

Pipeline by Audion Therapeutics BV, H2 2019

Pipeline by Ayala Pharmaceuticals Inc, H2 2019

Pipeline by Bristol-Myers Squibb Co, H2 2019

Pipeline by Cotinga Pharmaceuticals Inc, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by Everfront Biotech Inc, H2 2019

Pipeline by Lipopharma Therapeutics SL, H2 2019

Pipeline by Merck & Co Inc, H2 2019

Pipeline by NeuroGenetic Pharmaceuticals Inc, H2 2019

Pipeline by Pharchoice Therapeutics Inc, H2 2019

Pipeline by Pipeline Therapeutics Inc, H2 2019

Pipeline by SpringWorks Therapeutics Inc, H2 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports